ISPH Income Statement - TTM - Ibnsina Pharma

Income Statement (TTM)

Ibnsina Pharma Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000,000 except per share units.

	2020 09-30	2020 12-31	2021 03-31	2021 06-30	2021 09-30	2021 12-31	2022 03-31	2022 06-30	2022 09-30	2022 12-31	2023 03-31	2023 06-30	2023 09-30	2023 12-31	2024 03-31	2024 06-30	2024 09-30	2024 12-31	2025 03-31	2025 06-30
Revenue	18,373	18,679	18,992	19,929	20,730	21,733	22,309	21,870	21,792	22,264	23,775	26,700	30,258	33,949	37,682	42,066	48,546	55,842	62,312	68,074
Change (%)		1.67	1.68	4.93	4.02	4.84	2.65	-1.97	-0.36	2.17	6.78	12.30	13.33	12.20	10.99	11.63	15.40	15.03	11.58	9.25
% of Revenue	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00

Cost Of Sales	16,835	17,212	17,498	18,402	19,147	20,103	20,657	20,234	20,224	20,648	22,008	24,669	27,982	31,434	34,934	38,922	44,882	51,446	57,267	62,441
Change (%)		2.24	1.66	5.17	4.05	5.00	2.75	-2.05	-0.05	2.10	6.59	12.09	13.43	12.34	11.13	11.42	15.31	14.63	11.31	9.04
% of Revenue	91.63	92.15	92.13	92.34	92.37	92.50	92.59	92.52	92.80	92.74	92.57	92.39	92.48	92.59	92.71	92.53	92.45	92.13	91.90	91.72

Gross Operating Profit	1,537	1,467	1,495	1,527	1,583	1,630	1,652	1,637	1,568	1,617	1,768	2,032	2,276	2,515	2,748	3,144	3,664	4,397	5,045	5,633
Change (%)		-4.59	1.90	2.18	3.62	2.97	1.40	-0.96	-4.18	3.10	9.33	14.93	12.04	10.50	9.25	14.41	16.55	19.99	14.75	11.66
% of Revenue	8.37	7.85	7.87	7.66	7.63	7.50	7.41	7.48	7.20	7.26	7.43	7.61	7.52	7.41	7.29	7.47	7.55	7.87	8.10	8.28

SG&A	793	847	808	862	869	784	901	923	987	1,142	1,189	1,226	1,301	1,373	1,493	1,640	1,834	2,146	2,360	2,646
Change (%)		6.87	-4.63	6.74	0.81	-9.80	14.93	2.43	6.96	15.63	4.15	3.08	6.15	5.54	8.76	9.83	11.81	17.05	9.96	12.12
% of Revenue	4.31	4.53	4.25	4.33	4.19	3.61	4.04	4.22	4.53	5.13	5.00	4.59	4.30	4.04	3.96	3.90	3.78	3.84	3.79	3.89

R&D
Change (%)
% of Revenue

OpEx	17,753	18,190	18,449	19,419	20,175	21,065	21,693	21,245	21,260	21,782	23,188	25,888	29,275	32,798	36,415	40,550	46,705	53,585	59,621	65,048
Change (%)		2.46	1.42	5.26	3.90	4.41	2.98	-2.06	0.07	2.46	6.45	11.64	13.08	12.03	11.03	11.36	15.18	14.73	11.26	9.10
% of Revenue	96.63	97.38	97.14	97.44	97.33	96.93	97.24	97.14	97.56	97.83	97.53	96.96	96.75	96.61	96.64	96.40	96.21	95.96	95.68	95.55

Operating Income	620	489	543	511	554	667	617	626	532	482	587	812	983	1,152	1,267	1,516	1,841	2,258	2,691	3,026
Change (%)		-21.17	11.21	-6.06	8.52	20.45	-7.60	1.45	-14.96	-9.35	21.74	38.39	21.04	17.10	10.00	19.66	21.46	22.64	19.19	12.44
% of Revenue	3.37	2.62	2.86	2.56	2.67	3.07	2.76	2.86	2.44	2.17	2.47	3.04	3.25	3.39	3.36	3.60	3.79	4.04	4.32	4.45

Interest Expense	-292	-255	-245	-257	-269	-284	-305	-331	-389	-477	-609	-778	-928	-1,044	-1,176	-1,368	-1,513	-1,686	-2,009	-2,283
Change (%)		-12.52	-3.87	4.52	4.69	5.81	7.46	8.34	17.58	22.64	27.66	27.75	19.33	12.44	12.69	16.25	10.60	11.48	19.14	13.62
% of Revenue	-1.59	-1.37	-1.29	-1.29	-1.30	-1.31	-1.37	-1.51	-1.79	-2.14	-2.56	-2.91	-3.07	-3.08	-3.12	-3.25	-3.12	-3.02	-3.22	-3.35

Net Income	284	225	225	241	266	315	324	298	192	173	186	216	227	214	239	303	446	615	698	782
Change (%)		-20.83	0.04	7.08	10.62	18.22	2.86	-7.84	-35.60	-10.18	7.63	16.27	5.11	-5.89	11.98	26.75	47.12	37.75	13.63	11.95
% of Revenue	1.54	1.20	1.18	1.21	1.28	1.45	1.45	1.36	0.88	0.78	0.78	0.81	0.75	0.63	0.63	0.72	0.92	1.10	1.12	1.15

Source: Capital IQ

Ibnsina Pharma - Income Statement (TTM)

Income Statement (TTM)